 - Arm I: Patients receive taxanetrastuzumab therapy for 6 weeks. While continuing taxanetrastuzumab therapy, patients then undergo 10 fractions of concurrent prophylactic cranial radiotherapy in the absence of disease progression or unacceptable toxicity. 